| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Chromogranin A Levels Can Predict Postoperative Survival Outcomes in Metastatic Small-Bowel Carcinoid: Presented at ENETS By Karen Dente BERLIN -- March 14, 2010 -- Persistent elevations in blood levels of the protein chromogranin A (CgA) after primary tumour resection of midgut carcinoid tumour may demonstrate continued and increasing disease burden, according to findings presented here at the 7th Annual European Neuroendocrine Tumor Society (ENETS) Conference. “There is a continued diversity of outcome in patients with midgut carcinoid since neuroendocrine tumours demonstrate heterogeneous behaviour based upon site of origin and specific histology,” the authors wrote. Researchers from the Mount Sinai School of Medicine, New York, New York, and colleagues used a neuroendocrine tumour database of 200 patients to identify cases of metastatic small-bowel carcinoid managed at a tertiary care referral centre from 1991 to 2007. A total of 56 patients were identified who fit the criteria. The aim of the study was to delineate the prognostic clinicopathologic features in patients with the disease. All patients underwent primary resection of the tumour. Survival was measured from the date of resection and calculated by Kaplan-Meier estimation. Median survival was 121 months and Kaplan-Meier 5-year survival was estimated to be around 83%. Increased CgA levels taken at year 1 and years 1 through 5 post operatively were found to be associated with decreased survival (P < .05), while other clinical parameters showed no correlation with survival outcome. Univariate analysis showed that increased postoperative year 1 levels of serotonin were also associated with decreased survival (P < .05). The study authors concluded that increased CgA over time is a significant indication of survival outcome and highlights the importance of following this biochemical marker longitudinally over time in these patients after primary resection of their tumour as it may suggest the need for more aggressive treatment. [Presentation title: Prognostic Clinicopathologic Factors in Longitudinally Followed Patients With Metastatic Small Bowel Carcinoid. Abstract C16]
|